Login | Register

Gilenya Successfully Treated Relapsing MS Patients For Up To 7 Years

At the 64th annual meeting of the American Academy of Neurology (AAN), Novartis will present new data that supports Gilenya's (fingolimod) efficacy and safety profile and introduce new data of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, -5R modulator) in its multiple sclerosis portfolio3...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *